- A Phase 1 study of oral ecnoglutide (1871-LB)
showed it to be safe and well tolerated and result in pronounced
weight loss (up to -6.76% after 6 weeks of dosing). Improved oral
bioavailability enables a 15 to 30 mg daily dose of oral
ecnoglutide to match or exceed the plasma exposure of weekly
subcutaneous GLP-1 analogs for weight loss.
- In a Phase 3 study in participants with type 2 diabetes
(T2DM) (742-P, 793-P), weekly subcutaneous ecnoglutide
resulted in robust HbA1c declines of up to -2.43% from baseline
after 24 weeks of treatment, with up to 35.2% of participants
reaching normoglycemia (HbA1c <5.7%) and 43.7% with weight
reductions ≥5%.
- Novel amylin analogs (788-P, 789-P) were
identified that showed potent in vitro activity. In preclinical
models, combination of amylin analogs with ecnoglutide demonstrated
a synergistic effect on body weight reduction, with improved
efficacy compared to combination of cagrilintide and semaglutide.
Moreover, a novel amylin development candidate was identified that
is stable at neutral pH, providing the opportunity to co-formulate
with ecnoglutide or other GLP-1 analogs to improve ease of
use for patients and reduce costs.
HANGZHOU, China and SAN FRANCISCO, June 21,
2024 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a
clinical-stage biopharmaceutical company focusing on discovering
and developing innovative therapies to treat metabolic disease,
today announced that the company will present positive results from
a Phase 3 clinical study of injectable ecnoglutide (XW003) in T2DM
patients and from a Phase 1 study for oral ecnoglutide (XW004) in
healthy and healthy obese participants, as well as preclinical data
for novel amylin analog programs, at the American Diabetes
Association (ADA) 84th Annual Conference.
Five posters, including one late-breaking poster, will be
presented. The ADA conference is being held in Orlando, FL June
21-24, 2024.
Late Breaking Poster Presentation (1871-LB): Saturday June 22, 12:30 PM
- 1:30 PM
"Phase 1 Topline Safety, Efficacy, and
Pharmacokinetics of Oral Ecnoglutide"
Poster Presentation (742-P): Sunday
June 23, 12:30 PM - 1:30
PM
"A Phase 3 Evaluation of cAMP Signaling Biased
GLP-1 Analog Ecnoglutide (XW003) in Adults with Type 2
Diabetes"
Poster Presentation (793-P): Sunday
June 23, 12:30 PM - 1:30
PM
"Biased GLP-1 analog ecnoglutide (XW003) has
improved efficacy relative to unbiased peptides"
Poster Presentation (789-P): Sunday
June 23, 12:30 PM - 1:30
PM
"Discovery of a Novel, Long-Acting Amylin
Receptor Agonist for Body Weight Control"
Poster Presentation (788-P): Sunday
June 23, 12:30 PM - 1:30
PM
"Synergistic Body Weight Reduction of GLP-1
Analog Ecnoglutide and Amylin Analogs in Preclinical Animal
Models"
About ecnoglutide
Glucagon-like peptide-1 (GLP-1) analogs are effective therapies
in managing type 2 diabetes, obesity, and have demonstrated
clinical potential as a treatment for MASH. Ecnoglutide is a
novel, biased, long-acting GLP-1 peptide analog optimized for
improved biological activity, cost-effective manufacturing, and
once weekly subcutaneous dosing. Ecnoglutide has demonstrated
treatment benefits for patients with type 2 diabetes and obesity
and is safe and well tolerated in Phase 1 through Phase 3 clinical
studies.
About Sciwind
Sciwind Biosciences is a clinical stage biopharmaceutical
company focusing on discovering and developing innovative therapies
to treat metabolic disease. Its product pipeline consists of
potentially first-in-class and best-in-class drug candidates,
including the long-acting GLP-1 peptide analog XW003 (Phase 3),
oral GLP-1 peptide analog XW004 (Phase 1), an oral small molecule
GLP-1 receptor agonist XW014 (Phase 1), and novel amylin analogs
(preclinical). Sciwind has developed multiple proprietary
technologies, including oral peptide and inhaled protein
therapeutic delivery platforms and identified a series of drug
candidates based on these core platform technologies. For more
information, visit www.sciwindbio.com.
View original
content:https://www.prnewswire.com/news-releases/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conference-302178846.html
SOURCE Hangzhou Sciwind Biosciences Co., Ltd.